Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.89
Year High
$4.87
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
P/B ratio for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
P/B ratio as of 2023: 7.07
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.07. At the end of 2022 the company had a P/B ratio of 6.49.
P/B ratio history for Jiangsu Hengrui Medicine Co., Ltd. from 1997 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 7.07 |
| 2022 | 6.49 |
| 2021 | 9.24 |
| 2020 | 19.35 |
| 2019 | 15.55 |
| 2018 | 9.89 |
| 2017 | 10.43 |
| 2016 | 7.18 |
| 2015 | 8.05 |
| 2014 | 4.92 |
| 2013 | 5.66 |
| 2012 | 4.97 |
| 2011 | 5.45 |
| 2010 | 9.12 |
| 2009 | 8.70 |
| 2008 | 6.93 |
| 2007 | 10.68 |
| 2006 | 8.59 |
| 2005 | 1.47 |
| 2004 | 1.38 |
| 2003 | 1.03 |
| 2002 | 1.38 |
| 2001 | 2.07 |
| 2000 | 3.14 |
| 1999 | 12.06 |
| 1998 | 13.85 |
| 1997 | 20.53 |